

Cross Shore Acquisition Corporation

30 August 2007

Completion of Merger

Cross Shore Acquisition Corporation (“Cross Shore”) announces today that, following the waiver or satisfaction of all conditions to the merger agreement, including the seeking of the requisite valuation opinion, it has now completed its reverse takeover of ReSearch Pharmaceutical Services, Inc. (the “Acquisition”).

Admission to trading on AIM of Cross Shore’s existing shares and warrants will be cancelled and an application has been made for 40,699,958 shares and 1,971,847 warrants to be re-admitted to trading on AIM. The cancellation and re-admission to trading of both the shares and warrants is expected to become effective at 8.00 a.m. on 31 August 2007, as is the Company’s change of name to ReSearch Pharmaceutical Services, Inc. The Company’s shares and warrants will trade under the symbols RPSE and RPSW, respectively.

Until that time, trading in Cross Shore shares and warrants will remain suspended.

Shareholders who have irrevocably elected to have their shares repurchased should submit their share certificate(s) to Capita Registrars, The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU, UK, as soon as possible. Shareholders should note that the repurchase value of \$5.65 per share will only be paid on delivery to Capita of the requisite share certificate(s). Any potential transfer of a Cross Shore share which is the subject of a repurchase election will not be registered by the Company. Any questions regarding delivery of share certificates should be directed to Capita.

ENQUIRIES:

Cross Shore Dennis Smith	+1 843 597 4760
ReSearch Pharmaceutical Services Dan Perlman	+1 215 540 0700
Arbuthnot Securities Limited Nominated Adviser and UK Broker James Steel / Guy Blakeney	+44 207 012 2000

*Arbuthnot Securities Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting as nominated adviser and UK broker to the Company in connection with Re-admission. Its responsibilities as the Company's nominated adviser under the AIM Rules are owed solely to the London Stock Exchange and are not owed to the Company or to any Director or Proposed Director or to any other person.*

*Arbuthnot Securities Limited is acting exclusively for the Company and for no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their clients or for providing advice in relation to the contents of this announcement or the Re-admission. No representation or warranty, express or implied, is made by Arbuthnot Securities Limited as to the contents of this announcement. The information contained in this announcement is not intended to inform or be relied upon by any subsequent purchasers of Cross Shore Shares or Warrants (whether on or off exchange) and accordingly no duty of care is accepted in relation to them.*

*The Directors and Proposed Directors of Cross Shore Acquisition Corporation accept responsibility, individually and collectively, for the information contained in this announcement and for compliance with the AIM Rules. To the best of the knowledge and belief of the Directors and Proposed Directors, who have taken all reasonable care to ensure that such is the case, the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.*

END